<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363224">
  <stage>Registered</stage>
  <submitdate>31/10/2012</submitdate>
  <approvaldate>7/11/2012</approvaldate>
  <actrnumber>ACTRN12612001183875</actrnumber>
  <trial_identification>
    <studytitle>Diffuse Brainstem Glioma Tumour Study: developing new treatment strategies for Diffuse Pontine Glioma</studytitle>
    <scientifictitle>Post mortem tumour donation for Diffuse Intrinsic Pontine Glioma  developing DIPG cell cultures to test novel therapeutic strategies</scientifictitle>
    <utrn>U1111-1136-5859</utrn>
    <trialacronym>HoTRODS</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diffuse Pontine Glioma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a tumour biology study whereby tumour and constitutional tissue samples from 12 patients from participating sites in Australia with diffuse pontine glioma  (DIPG) and other types of brainstem gliomas will be collected at autopsy, culture the DIPG cells in vivo and perform a screen of 10,000 small molecules that specifically inhibit diffuse pontine glioma propagation and identify these molecules to develop new treatment strategies for Diffuse Pontine Glioma.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>develop new treatment strategies for diffuse pontine glioma by culturing cells from autopsy specimens in vivo and identifying cells/molecules that inhibit the propagation of diffuse pontine glioma</outcome>
      <timepoint>at the end of study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>harvest diffuse pontine glioma specimens, grow viable stem cells and culture new cell lines</outcome>
      <timepoint>at the end of the study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. patients of any age with clinical and radiologic diagnosis of diffuse brainstem glioma
2. Patients with other high-grade gliomas originating in the brainstem
3. patients with focal gliomas (WHO grade I/II) of the brainstem</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients with any type of infiltrative low-grade (WHO grade II) or high grade glioma (WHO grade III and IV) originating outside the brainstem.
2. Patients harbouring primary brainstem tumours with other histologic diagnoses (e.g. PNET)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>17/07/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2031</postcode>
    <postcode>2145</postcode>
    <postcode>2035</postcode>
    <postcode>3051</postcode>
    <postcode>5006</postcode>
    <postcode>6008</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr. David Ziegler</primarysponsorname>
    <primarysponsoraddress>Centre for Children's Cancer and Blood Disorders
Sydney Children's Hospital
Level 1 High Street
Randwick, NSW 2031</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Kids Cancer Alliance</fundingname>
      <fundingaddress>Level 5
C25 Lowy Cancer Research Centre
Gate 9 High St
UNSW Sydney NSW 2052</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Charities/Societies/Foundations</othercollaboratortype>
      <othercollaboratorname>Kids Cancer Alliance</othercollaboratorname>
      <othercollaboratoraddress>Level 5
C25 Lowy Cancer Research Centre
Gate 9 High St
UNSW Sydney NSW 2052</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main goal of the study is to grow cells in the laboratory from tumours of patients with diffuse brainstem glioma and similar brainstem tumours. The aim of the results of the study is to help develop new and better treatments for patients with these types of tumours and help in choosing the right treatment for each patient and be able to predict which patients are more likely or not to respond to a certain type of treatment</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Ethics and Governance Unit
Locked Bag No.1
New Lambton, NSW 2035</ethicaddress>
      <ethicapprovaldate>12/07/2012</ethicapprovaldate>
      <hrec>12/HNE/111</hrec>
      <ethicsubmitdate>28/03/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. David Ziegler</name>
      <address>Centre for Children's Cancer and Blood Disorders
Sydney Children's Hospital
Level 1 South
High Street
Randwick, NSW 2031</address>
      <phone>+61(0)2 9382 1730</phone>
      <fax>+61 (0)2 9382 1789</fax>
      <email>d.ziegler@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. David Ziegler</name>
      <address>Centre for Children's Cancer and Blood Disorders
Sydney Children's Hospital
Level 1 South
High Street
Randwick, NSW 2031</address>
      <phone>+61(0)2 9382 1730</phone>
      <fax>+61 (0)2 9382 1789</fax>
      <email>d.ziegler@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Geraldine Bicol</name>
      <address>Centre for Children's Cancer and Blood Disorders
Sydney Children's Hospital
Level 1 South
High Street
Randwick, NSW 2031</address>
      <phone>+61(0)2 9382 0710</phone>
      <fax>+61 (0)2 9382 1789</fax>
      <email>Geraldine.Bicol@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>